Perioperative treatment

Phase 2Small molecule

PPeking University Cancer Hospital & Institute

Perioperative treatment is one of 83 small molecule programs targeting Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

AdenocarcinomaRecruiting

Gastric CancerActive, not recruiting

AdenocarcinomaPhase 2

Recruiting

Gastric CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

193 competitors in Gastric Cancer

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

44 2

Camptosar

Pfizer

Phase 3

23 3

Keytruda

Merck & Co.

Phase 3

19 4

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

55 5

Taxotere

AAvyxa

Phase 3

45 6

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

91 7

Abraxane

Bristol-Myers Squibb

Phase 3

11 8

Beyfortus

BeiGene

Phase 3

10 9

Elunate

Takeda

Phase 3

7 10

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Gastric Cancer

NCT04736485

Q4 2029

Phase 2Recruiting

Adenocarcinoma

NCT06992362

Clinical

Trials by Indication[1]

Gastric Cancer1 trial

Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT)

Active, not recruiting·CCentre Francois Baclesse·Phase 2·NCT04736485·67 enrolled

Adenocarcinoma1 trial

Perioperative Treatment of Hepatoid Adenocarcinoma of Stomach

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT06992362·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Perioperative treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Perioperative treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Perioperative treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Peking University Cancer Hospital & Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPeking University Cancer Hospital & Institute

Perioperative treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2029

Trials by Indication[1]

Gastric Cancer1 trial

Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News